HRP20100157T1 - Retard tablete hidromorfona - Google Patents

Retard tablete hidromorfona Download PDF

Info

Publication number
HRP20100157T1
HRP20100157T1 HR20100157T HRP20100157T HRP20100157T1 HR P20100157 T1 HRP20100157 T1 HR P20100157T1 HR 20100157 T HR20100157 T HR 20100157T HR P20100157 T HRP20100157 T HR P20100157T HR P20100157 T1 HRP20100157 T1 HR P20100157T1
Authority
HR
Croatia
Prior art keywords
active substance
layer
release
tablet
layer containing
Prior art date
Application number
HR20100157T
Other languages
English (en)
Croatian (hr)
Inventor
Zingraff Marc
Reher Markus
Original Assignee
Acino Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100157(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acino Pharma Ag filed Critical Acino Pharma Ag
Publication of HRP20100157T1 publication Critical patent/HRP20100157T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
HR20100157T 2007-11-09 2010-03-18 Retard tablete hidromorfona HRP20100157T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07021788A EP2057984B1 (de) 2007-11-09 2007-11-09 Retardtabletten mit Hydromorphon

Publications (1)

Publication Number Publication Date
HRP20100157T1 true HRP20100157T1 (hr) 2010-04-30

Family

ID=39272211

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100157T HRP20100157T1 (hr) 2007-11-09 2010-03-18 Retard tablete hidromorfona

Country Status (15)

Country Link
US (1) US20100247647A1 (pl)
EP (3) EP2057984B1 (pl)
JP (1) JP2011503017A (pl)
AT (2) ATE455538T1 (pl)
AU (1) AU2008324466A1 (pl)
CA (1) CA2704646C (pl)
DE (1) DE502007002695D1 (pl)
DK (2) DK2057984T3 (pl)
ES (2) ES2337935T3 (pl)
HR (1) HRP20100157T1 (pl)
PL (1) PL2057984T3 (pl)
PT (1) PT2057984E (pl)
RS (1) RS51313B (pl)
SI (1) SI2057984T1 (pl)
WO (1) WO2009059701A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2932964A1 (en) 2000-10-30 2015-10-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
JP5894717B2 (ja) * 2009-12-17 2016-03-30 シマ ラブス インク． 乱用抑止性製剤
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
EP2446882B8 (de) * 2010-10-28 2014-02-12 Acino Pharma AG Arzneimittel mit dem Wirkstoff Hydromorphon mit verbesserter Lagerstabilität
EP2606879A1 (en) * 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
WO2014034929A1 (ja) * 2012-09-03 2014-03-06 第一三共株式会社 ヒドロモルフォン塩酸塩含有の経口用徐放性医薬組成物
CA2795324C (en) * 2012-11-09 2015-07-14 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
JP6696994B2 (ja) 2014-12-08 2020-05-20 クレシオ・バイオサイエンシズ・リミテッド 即放性乱用抑止性顆粒剤形
WO2019101832A1 (en) 2017-11-27 2019-05-31 Dsm Ip Assets B.V. Freeze-dried multiparticulate solid dosage form
TW201943410A (zh) 2018-04-10 2019-11-16 荷蘭商帝斯曼知識產權資產管理有限公司 具有彈性結構之多顆粒固體劑型
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
DE19927688A1 (de) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
WO2004112746A1 (en) * 2003-06-26 2004-12-29 Korea Research Institute Of Chemical Technology Controlled release-drug delivery system for oral administration
EP1677768A4 (en) * 2003-10-03 2011-06-29 Elite Lab Inc PROLONGED RELEASE OPIOID FORMULATIONS AND METHOD OF USING THE FORMULATIONS
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20070104789A1 (en) * 2005-11-04 2007-05-10 Donald Spector Gastro-resistant and ethanol-resistant controlled-release formulations comprising hydromorphone
JP5349059B2 (ja) * 2006-03-06 2013-11-20 ポーゼン インコーポレイテッド 薬物の組み合わせを投与するための剤形

Also Published As

Publication number Publication date
PT2057984E (pt) 2010-03-10
CA2704646C (en) 2016-04-05
ATE536862T1 (de) 2011-12-15
PL2057984T3 (pl) 2010-05-31
SI2057984T1 (sl) 2010-04-30
AU2008324466A1 (en) 2009-05-14
EP2057984B1 (de) 2010-01-20
WO2009059701A2 (de) 2009-05-14
CA2704646A1 (en) 2009-05-14
ATE455538T1 (de) 2010-02-15
EP2425822B1 (de) 2012-12-19
DK2057984T3 (da) 2010-05-03
RS51313B (sr) 2010-12-31
EP2217210B1 (de) 2011-12-14
ES2374690T3 (es) 2012-02-21
US20100247647A1 (en) 2010-09-30
DE502007002695D1 (de) 2010-03-11
EP2425822A1 (de) 2012-03-07
WO2009059701A3 (de) 2009-07-16
EP2057984A1 (de) 2009-05-13
DK2217210T3 (da) 2012-02-13
JP2011503017A (ja) 2011-01-27
EP2217210A2 (de) 2010-08-18
ES2337935T3 (es) 2010-04-30

Similar Documents

Publication Publication Date Title
HRP20100157T1 (hr) Retard tablete hidromorfona
ME00391B (me) Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
HRP20171458T1 (hr) Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
EA201071054A1 (ru) Твердый препарат, растворяющийся во рту
WO2006123357A3 (en) Oral controlled release composition containing levetiracetam
WO2008132710A3 (en) Pharmaceutical nimodipine compositions
HRP20140946T1 (hr) Terapeutske kompozicije koje sadrže rilpivirin hcl i tenovofir dizoproksil fumarat
WO2006084474A3 (en) A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor
JO2555B1 (en) Forms of oral doses of propiferine or pharmaceutically acceptable salts thereof with an extended release of active agent
NO20052515L (no) Frigjoringskontrollerte sammensetninger
WO2009034431A3 (en) Controlled-release dosage forms for varenicline
RS54329B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE, PROCEDURES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS
TR200801942T1 (tr) Hacim kazandırıcı maddeler
JP2010540547A5 (pl)
IL190305A0 (en) Controlled release, pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof
HRP20151347T1 (hr) Nova kombinacija
WO2011140446A3 (en) Pharmaceutical formulations
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
JP2015508411A5 (pl)
DK1677777T3 (da) Pellets indeholdende venlafaxin-hydrochlorid
WO2011141791A3 (en) Extended release formulations of desvenlafaxine base
BRPI0507765A (pt) comprimidos revestidos compressos e sua produção
MX2009013054A (es) Composicion farmaceutica que comprende un sustrato y un revestimiento que contiene un ingrediente activo y alcohol polivinilico.
WO2011093612A3 (en) Oral complex composition comprising pseudoephedrine and levocetirizine
WO2008038155A3 (en) Controlled-release pharmaceutical tablets